Prevalence of COVID-19 in patients with parkinson’s disease and the impact of parkinson’s disease on COVID-19 prognosis
- 09.09.2025
- Research
Erschienen in:
- Verfasst von
-
Demet Yildiz
Korrespondierender Autor Demet Yildiz
- Department of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
-
Nilüfer Büyükkoyuncu Pekel
Nilüfer Büyükkoyuncu Pekel
- Department of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
-
Melih Yüksel
Melih Yüksel
- Department of Emergency Medicine, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
-
Aksel özdemir
Aksel özdemir
- Department of Emergency Medicine, Kadirli State Hospital, Adana, Turkey
-
Ebru çetin kenan
Ebru çetin kenan
- Department of Emergency Medicine, Bursa City Hospital, Bursa, Turkey
-
Muhammed Furkan öztürkci
Muhammed Furkan öztürkci
- Department of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
- Erschienen in
- Acta Neurologica Belgica | Ausgabe 6/2025
Abstract
Objective
This study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson’s disease (PD), along with the clinical course and factors associated with mortality.
Methods
A total of 1,786 patients diagnosed with Parkinson’s disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.51% in the PD population. Due to insufficient data, 63 of the COVID-19 positive patients were excluded. The final study cohort included 177 patients: 89 patients with PD (50.3%) and 88 age- and sex-matched controls (49.7%). Clinical, laboratory, and prognostic parameters were compared between groups.
Results
The prevalence of dementia was significantly higher in the PD group. Mortality at both 28 and 90 days was also significantly increased among patients with PD. Notably, those receiving combined therapy with dopamine agonists and levodopa had lower mortality rates at both time points. In patients who died within 28 or 90 days, levels of age, neutrophil count, lymphocyte count, D-dimer, ferritin, C-reactive protein (CRP), and troponin differed significantly compared to survivors.
Conclusion
Patients with Parkinson’s disease represent a vulnerable population at increased risk for adverse outcomes from COVID-19. Close clinical monitoring, continuous dopaminergic treatment, and a personalized approach are essential for optimizing management during COVID-19 infection.
Anzeige
- Titel
- Prevalence of COVID-19 in patients with parkinson’s disease and the impact of parkinson’s disease on COVID-19 prognosis
- Verfasst von
-
Demet Yildiz
Nilüfer Büyükkoyuncu Pekel
Melih Yüksel
Aksel özdemir
Ebru çetin kenan
Muhammed Furkan öztürkci
- Publikationsdatum
- 09.09.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
Acta Neurologica Belgica / Ausgabe 6/2025
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993 - DOI
- https://doi.org/10.1007/s13760-025-02888-8
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
